報價延遲最少15分鐘:2024/05/20 14:13 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.3806 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.38/-3.16
|
|
企業價值
303.59M
|
| 資產負債 |
|
每股賬面淨值
1.69
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
57.19M
|
|
每股收益
1.90
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/20 14:13 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 CTLA-4), Tebotelimab (PD-1 LAG-3), MGD024 (CD123 CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV CD3). |